Clinical Trial Update: A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating AK112 as monotherapy in advanced or metastatic renal cell carcinoma, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AK112

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING